UBS Group’s Precision BioSciences DTIL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $461K | Sell |
58,699
-22,434
| -28% | -$158K | ﹤0.01% | 6283 |
|
|
2026
Q1 | $446K | Buy |
81,133
+19,801
| +32% | +$91.4K | ﹤0.01% | 6159 |
|
|
2025
Q4 | $255K | Buy |
61,332
+36,856
| +151% | +$209K | ﹤0.01% | 6453 |
|
|
2025
Q3 | $135K | Sell |
24,476
-27,130
| -53% | -$130K | ﹤0.01% | 6919 |
|
|
2025
Q2 | $217K | Sell |
51,606
-5,421
| -10% | -$26.7K | ﹤0.01% | 6665 |
|
|
2025
Q1 | $272K | Sell |
57,027
-11,588
| -17% | -$59K | ﹤0.01% | 6325 |
|
|
2024
Q4 | $261K | Buy |
68,615
+66,732
| +3,544% | +$487K | ﹤0.01% | 6293 |
|
|
2024
Q3 | $16.9K | Buy |
1,883
+1,676
| +810% | +$16.1K | ﹤0.01% | 7466 |
|
|
2024
Q2 | $2.01K | Buy |
207
+1
| +0.5% | +$12 | ﹤0.01% | 8441 |
|
|
2024
Q1 | $2.79K | Sell |
206
-2,752
| -93% | -$33.7K | ﹤0.01% | 7827 |
|
|
2023
Q4 | $32.4K | Buy |
2,958
+300
| +11% | +$3.24K | ﹤0.01% | 6803 |
|
|
2023
Q3 | $27.2K | Buy |
2,658
+497
| +23% | +$7.64K | ﹤0.01% | 6641 |
|
|
2023
Q2 | $34.1K | Buy |
2,161
+2,056
| +1,958% | +$47K | ﹤0.01% | 6664 |
|
|
2023
Q1 | $2.37K | Sell |
105
-505
| -83% | -$16.6K | ﹤0.01% | 8524 |
|
|
2022
Q4 | $21.8K | Buy |
610
+486
| +392% | +$19.2K | ﹤0.01% | 7564 |
|
|
2022
Q3 | $5K | Buy |
124
+86
| +226% | +$4.09K | ﹤0.01% | 9185 |
|
|
2022
Q2 | $2K | Hold |
38
| – | – | ﹤0.01% | 9532 |
|
|
2022
Q1 | $4K | Sell |
38
-4,762
| -99% | -$647K | ﹤0.01% | 9285 |
|
|
2021
Q4 | $1.07M | Buy |
4,800
+1,920
| +67% | +$536K | ﹤0.01% | 4334 |
|
|
2021
Q3 | $997K | Buy |
2,880
+2,304
| +400% | +$781K | ﹤0.01% | 4200 |
|
|
2021
Q2 | $217K | Sell |
576
-10,430
| -95% | -$3.13M | ﹤0.01% | 5279 |
|
|
2021
Q1 | $3.42M | Buy |
11,006
+6,450
| +142% | +$2.26M | ﹤0.01% | 3000 |
|
|
2020
Q4 | $1.14M | Sell |
4,556
-2,180
| -32% | -$534K | ﹤0.01% | 3904 |
|
|
2020
Q3 | $1.24M | Buy |
6,736
+6,283
| +1,387% | +$1.25M | ﹤0.01% | 3480 |
|
|
2020
Q2 | $114K | Sell |
453
-97
| -18% | -$21.2K | ﹤0.01% | 5199 |
|
|
2020
Q1 | $100K | Sell |
550
-823
| -60% | -$215K | ﹤0.01% | 5291 |
|
|
2019
Q4 | $572K | Buy |
1,373
+1,236
| +902% | +$388K | ﹤0.01% | 4718 |
|
|
2019
Q3 | $34K | Sell |
137
-1,956
| -93% | -$637K | ﹤0.01% | 6413 |
|
|
2019
Q2 | $832K | Buy |
2,093
+1,783
| +575% | +$718K | ﹤0.01% | 3896 |
|
|
2019
Q1 | $167K | Buy |
+310
| New | +$165K | ﹤0.01% | 4728 |
|
Other funds holding DTIL
BL
LCM
EAM
UBS Group's DTIL Position: Q2 2026 in Review
UBS Group reduced its Precision BioSciences (DTIL) stake by 28% in Q2 2026, selling an estimated $158K and leaving 58,699 shares worth $461K. The position accounts for ﹤0.01% of the portfolio, ranked #6283.
UBS Group first reported a position in DTIL in Q1 2019 and has held it in 30 quarters since. The position peaked at $3.42M in Q1 2021. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.
- UBS Group held 58,699 shares of Precision BioSciences worth $461K as of Q2 2026.
- UBS Group sold 22,434 Precision BioSciences shares in Q2 2026, an estimated $158K.
- Precision BioSciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6283 holding.
- UBS Group first reported a position in Precision BioSciences in Q1 2019 and has held it in 30 quarters since.
- UBS Group's Precision BioSciences position peaked at $3.42M in Q1 2021.
- 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.